目的 研究通心絡膠囊聯(lián)合吲達帕胺治療高血壓合并冠心病的臨床療效。方法 選取2013年3月-2015年3月商洛市中心醫(yī)院收治的高血壓合并冠心病患者100例，隨機分為對照組和治療組，每組各50例。對照組患者口吲達帕胺緩釋片，1片/次，1次/d。治療組患者在對照組治療基礎上口服通心絡膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療1個月。觀察兩組的臨床療效，同時比較兩組患者治療前后心電圖和血脂變化情況。結果 治療后，對照組和治療組的總有效率分別為82.0%、94.0%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者ST段壓低、ST段抬高、房性期前收縮和室性期前收縮的患者例數(shù)均顯著減少，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療組下降程度優(yōu)于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組三酰甘油（TG）、總膽固醇（TC）和低密度脂蛋白（LDL-C）顯著降低，高密度脂蛋白（HDL-C）顯著升高，同組治療前后差異有統(tǒng)計學意義（P<0.05）；治療組這些指標的改善程度優(yōu)于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 通心絡膠囊聯(lián)合吲達帕胺治療高血壓合并冠心病具有較好的臨床療效，可以顯著降低血脂水平，改善心電圖情況，具有一定的臨床推廣應用價值。

Objective To study the effect of Tongxinluo Capsules combined with indapamide in treatment of hypertension with coronary heart disease. Methods Patients (100 cases) with hypertension with coronary heart disease in Shangluo Central Hospital from March 2013 to March 2014 were randomly divided into control and treatment groups, and each group had 50 cases. The patients in the control group were po administered with Indapamide Sustained-release Tablets, 1 tablet/time, once daily. The patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the changes of the electrocardiogram and blood lipids in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.0% and 94.0%, respectively, and there were differences between two groups (P<0.05). After treatment, patients in two groups with ST segment depression, ST segment elevation, premature atrial contraction, and ventricular premature contraction were significantly reduced, and the difference was statistically significant in the same group (P<0.05). And the descending degree in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, TG, TC, and LDL-C in two groups were significantly decreased, and HDL-C was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, those observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusions Tongxinluo Capsules combined with indapamide has clinical curative effect in treatment of hypertension with coronary heart disease, and can significantly reduce blood lipid levels, also can improve the electrocardiogram, which has a certain clinical application value.